<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280682</url>
  </required_header>
  <id_info>
    <org_study_id>2010-SR-021</org_study_id>
    <nct_id>NCT01280682</nct_id>
  </id_info>
  <brief_title>Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes</brief_title>
  <official_title>Immune Intervention With Anti-CD20 Monoclonal Antibody to Preserve Beta Cell Function in Early Onset Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transient elimination of B lymphocytes with anti-CD20 monoclonal antibody would decrease
      immune-mediated destruction of beta cells and result in preserved beta-cell function in
      patients with type 1 diabetes of recent onset.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the presence of autoantibodies is a diagnostic criterion, the immunopathogenesis of
      beta-cell destruction in type 1 diabetes is typically associated with T-lymphocyte
      autoimmunity.

      Many T-lymphocyte-mediated diseases include a B-lymphocyte component. B lymphocytes can play
      a crucial role as antigen-presenting cells, expressing high levels of class II
      major-histocompatibility-complex antigens and generating cryptic peptides to which T
      lymphocytes are not tolerant.

      B lymphocytes can be selectively depleted with the anti-CD20 monoclonal antibody. We will
      test the hypothesis that transient elimination of B lymphocytes with anti-CD20 monoclonal
      antibody would decrease immune-mediated destruction of beta cells and result in preserved
      beta-cell function in patients with type 1 diabetes of recent onset.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD19+ cells</measure>
    <time_frame>1 week later</time_frame>
    <description>number of CD19+ cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-peptide level</measure>
    <time_frame>6 monthes later</time_frame>
    <description>C-peptide level during the first 2 hours of a mixed meal tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glycated hemoglobin level</measure>
    <time_frame>6 monthes later</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insulin dose</measure>
    <time_frame>6 monthes later</time_frame>
    <description>insulin dose(u/Kg)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>anti-CD20 monoclonal antibody 125mg/m^2 day1 day8 day15 day22 repeat after six months (only day1 and day8)</description>
    <arm_group_label>rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of type 1 diabetes

          -  The age of subjects between 8 and 45 years old

          -  Course of disease within 1 year

          -  Presence of at least one type of detectable islet autoantibody [zinc transporter 8
             antibody(ZnT8A),glutamic acid decarboxylase antibody(GADA),protein tyrosine
             phosphatase-2 antibody(IA-2A),insulin autoantibody(IAA)]

          -  Stimulated peak C-peptide levels of at least 0.2 pmol/mL

        Exclusion Criteria:

          -  Confirmed diagnosis of type 2 diabetes

          -  Severe chronic or acute complications of diabetes

          -  Severe infection or damage to the immune response

          -  Presence of chronic latent infection in vivo

          -  Viral hepatitis B patients whose hepatitis B virus(HBV)DNA &gt; log10^5

          -  Liver and kidney dysfunction, alanine aminotransferase(ALT), aspartate
             aminotransferase(AST), and creatinine more than 2 times the upper limit of normal

          -  Hypotension, systolic blood pressure(SBP) ≤ 90mmHg, diastolic blood pressure(DBP) ≤
             60mmHg

          -  Patients with rheumatoid arthritis

          -  Allergic to any component of this drug

          -  Pregnancy, breast-feeding women

          -  Use of other immunosuppressive agents 3 months before selected
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tao Yang, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Nanjing Medical University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tao Yang, MD/PhD</last_name>
    <phone>86-25-83718836</phone>
    <phone_ext>6466</phone_ext>
    <email>yangt@njmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Affiliated Hospital, Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Yang, PhD</last_name>
      <phone>86-25-83718836</phone>
      <phone_ext>6466</phone_ext>
      <email>yangt@njmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Tao Yang, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 29, 2010</study_first_submitted>
  <study_first_submitted_qc>January 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2011</study_first_posted>
  <last_update_submitted>January 19, 2011</last_update_submitted>
  <last_update_submitted_qc>January 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Department of Endocrinology &amp; Metabolism</name_title>
    <organization>Department of Endocrinology &amp; Metabolism</organization>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <keyword>age</keyword>
  <keyword>course of disease</keyword>
  <keyword>autoantibodies</keyword>
  <keyword>C-peptide levels</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>October 16, 2012</submitted>
    <returned>November 14, 2012</returned>
    <submitted>November 19, 2012</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>November 25, 2012</submitted>
    <returned>December 24, 2012</returned>
    <submitted>August 29, 2013</submitted>
    <returned>October 31, 2013</returned>
    <submitted>September 22, 2016</submitted>
    <returned>November 9, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

